A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/1997
12/04/1997	DE19622222A1 Use of sodium=proton exchange inhibitor
12/04/1997	CA2256693A1 Method for monitoring t-cell reactivity
12/04/1997	CA2256588A1 Methods and compositions useful for inhibition of .alpha.v.beta.5 mediated angiogenesis
12/04/1997	CA2256481A1 Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
12/04/1997	CA2253818A1 Mammalian tolloid-like gene and protein
12/04/1997	CA2253410A1 New improved formulation for treatment of thromboembolism
12/03/1997	EP0809708A1 Potentiators of antibacterial agents
12/03/1997	EP0809701A1 Calcineurin regulatable adenylate cyclase
12/03/1997	EP0809517A1 Anti-transforming growth factor-beta gene therapy
12/03/1997	EP0809516A1 Medicinal combination useful for in vivo exogenic transfection and expression
12/03/1997	EP0809500A1 Novel glucocorticoid response elements
12/03/1997	EP0809498A1 Novel pharmaceutical combination
12/03/1997	EP0809490A1 Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection
12/03/1997	CN1166786A Retroviral protease inhibitor combinations
12/03/1997	CN1166785A Pharmaceutical control of inflammation
12/02/1997	US5693775 Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
12/02/1997	US5693676 Using nitroglycerin to treat anal fissures or ulcers, hemorrhoids, levator spasms
12/02/1997	US5693654 Medicaments for treating intraocular pressure
12/02/1997	US5693623 Topical preparations for the treatment of acne and acneiform dermatitis
12/02/1997	US5693492 Purified dna molecule encoding drosophila avermectin and/or glutamate binding protein which functions as glutamate-gated anion channel
12/02/1997	US5692302 Wound healing agent comprises pyruvic acid or salt, antioxidant, fatty acid mixture
11/1997
11/27/1997	WO1997044468A1 HUMAN INTERLEUKIN-1j AND ANTAGONISTS THEREOF
11/27/1997	WO1997044461A2 Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
11/27/1997	WO1997044454A2 Human phospholipase inhibitor
11/27/1997	WO1997044441A1 New antigen presenting cells, a process for preparing the same and their use as cellular vaccines
11/27/1997	WO1997044360A1 Novel human g-protein coupled receptor
11/27/1997	WO1997044359A1 Novel human g-protein coupled receptor
11/27/1997	WO1997044357A1 Synthetic glucagon binding proteins
11/27/1997	WO1997044322A1 Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
11/27/1997	WO1997044062A1 The use of 5-ht1b/1d agonists to treat ocular pain
11/27/1997	WO1997044058A1 Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same
11/27/1997	WO1997044054A2 Type-2 chemokine binding proteins and methods of use therefor
11/27/1997	WO1997044053A1 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid
11/27/1997	WO1997044052A1 Immunomodulating compounds comprising d-isomers of amino acids
11/27/1997	WO1997044045A1 Malatonin in combination with analgesics
11/27/1997	WO1997044036A1 Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors
11/27/1997	WO1997044035A1 Methods of treating hypertension
11/27/1997	WO1997044032A1 Anti-vaginitis composition for topical use comprising one or more anti-vaginitis medicaments and one or more local anaesthetics
11/27/1997	WO1997044026A1 Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
11/27/1997	WO1997044024A1 Novel arachidonic acid metabolite, 16-hete
11/27/1997	WO1997043902A1 Use of gaba uptake inhibitors as anti-tussive agents
11/27/1997	WO1997035976A3 Epidermal differentiation factor
11/27/1997	CA2258698A1 Immunomodulating compounds comprising d-isomers of amino acids
11/27/1997	CA2256578A1 Novel arachidonic acid metabolite, 16-hete
11/27/1997	CA2256568A1 Type-2 chemokine binding proteins and methods of use therefor
11/27/1997	CA2256109A1 Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same
11/27/1997	CA2255910A1 Methods of treating hypertension
11/27/1997	CA2255906A1 Human interleukin-1j and antagonists thereof
11/27/1997	CA2255838A1 Melatonin in combination with analgesics
11/27/1997	CA2255640A1 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid
11/27/1997	CA2255541A1 Synthetic glucagon binding proteins
11/27/1997	CA2253541A1 Human phospholipase inhibitor
11/27/1997	CA2252531A1 Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors
11/27/1997	CA2252501A1 Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
11/26/1997	EP0808900A2 Polynucleotides and polypeptides associated with benign prostatic hypertrophy
11/26/1997	EP0808899A2 Human marco scavenger receptor (HMarcoSR)
11/26/1997	EP0808897A1 New antigen presenting cells, a process for preparing the same and their use as cellular vaccines
11/26/1997	EP0808844A2 Antisense oligonucleotides complementary to the primary transcript of the human c-fes protooncogene and their use, combined with a differentiation inducer to cause apoptosis of leukemic blast cells
11/26/1997	EP0808628A2 Use of non-peptide bradykinin antagonists for treating and preventing chronic fibrogenetic liver diseases, acute liver diseases and complications thereof
11/26/1997	EP0808627A2 Use of non-peptide bradykinin antagonists for treating and preventing chronic fibrogenetic liver diseases, acute liver diseases and complications thereof
11/26/1997	EP0808366A1 IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF
11/26/1997	EP0808172A2 Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist
11/26/1997	EP0808171A2 Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
11/26/1997	EP0808168A1 Pharmaceutical composition for the treatment of herpes
11/26/1997	EP0808165A1 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
11/26/1997	EP0808164A1 Method for treatment of obesity using prolactin modulators and diet
11/26/1997	EP0808162A2 Use of carbazole compounds for the treatment of congestive heart failure
11/26/1997	EP0808157A1 Medicated tissue paper product
11/26/1997	EP0686037A4 Hormone replacement therapy
11/26/1997	EP0662130B1 A method of producing hepatocyte growth factor and a cell line
11/25/1997	US5691387 Treatment of sickle cell anemia with nonionic surfactants
11/25/1997	US5691378 Method for treating wrinkles using combinations of alpha hydroxyacids and/or alpha ketoacids
11/25/1997	US5691375 Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
11/25/1997	US5691338 1,2-dithiole-3 thiones for the treatment of reverse transcriptase-dependent viral infections
11/25/1997	US5691320 Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
11/25/1997	US5691318 Nervous system disorders and medical diagnosis
11/25/1997	US5691306 Protein secretion
11/25/1997	US5690967 Compositions for improved topical delivery of lactic acid
11/25/1997	US5690946 Cosmetic and/or dermatological composition containing thermal spring water or mineral water and an active agent, in order to combat acne or aging
11/25/1997	US5690944 Cosmetic compositions containing lactate dehydrogenase inhibitors
11/25/1997	US5690929 Use of methioninase and chemotherapy agents in chemotherapy
11/22/1997	CA2205780A1 Use of nonpeptide bradykinin antagonists for the treatment and prevention of chronic fibrogenetic liver disorders, acute liver disorders and the complications associated therewith
11/20/1997	WO1997043649A1 CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrP?sc¿
11/20/1997	WO1997043431A1 Vehicle for the transport of molecular substances
11/20/1997	WO1997043311A1 Anticoagulant peptide fragments derived from apolipoprotein b-100
11/20/1997	WO1997043304A1 Novel compounds
11/20/1997	WO1997043303A1 Novel compounds
11/20/1997	WO1997042980A1 Methods of terminal sterilization of biological products
11/20/1997	WO1997042968A2 Administration of histamine for therapeutic purposes
11/20/1997	WO1997042964A1 Method and product for promoting hair growth and treating skin conditions
11/20/1997	WO1997042962A1 Formulation for use in the prevention of pathogen induced diseases including hiv and hsv
11/20/1997	WO1997042959A1 Emergency contraceptive kit
11/20/1997	WO1997042939A1 Liposomal antineoplaston therapies with markedly improved antineoplastic activity
11/20/1997	WO1997042825A1 Antimicrobial peroxidase compositions
11/20/1997	WO1997038664A3 A method of treating cancer
11/20/1997	WO1997035538A3 Tumor necrosis factor alpha convertase
11/20/1997	DE19632823C1 Complexes of (+)-S-adenosyl-methionine and 3'-azido-2',3'-di:deoxy nucleoside compounds
11/20/1997	CA2253365A1 Administration of histamine for therapeutic purposes
11/20/1997	CA2253289A1 Emergency contraceptive kit
11/20/1997	CA2247392A1 Vehicle for the transport of molecular substances

1 ... 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 ... 1151